Entry into orphan drug development and contract services
First written in FY2024. 6 of 7 entries say "Advanced", first in FY2025. Latest entry: 2026-10-14.
No other company in this theme has enough history to compare yet.
- 2026-10-14AdvancedEarnings presentation
「8月25日、当社が治験薬を設計・製造し、ノーベルファーマ社が開発を進める多系統萎縮症(MSA)を適応症とするユビキノール含有製剤「NPC-29」について、厚生労働省（医薬局医薬品審査管理課）より「先駆的医薬品」に指定」
NPC-29が臨床試験開始・治験薬投与開始の段階から、厚生労働省による「先駆的医薬品」指定の段階へ進展した。 - FY2026AdvancedAnnual report
「Regarding NPC-29, a ubiquinol-containing formulation being developed by one of its partner companies, ノーベルファーマ株式会社, a Phase III clinical trial has begun, accompanied by the start of administration of the investigational drug manufactured by the Company.」
In the orphan drug business, NPC-29 progressed from the basic development agreement and discussion stage to the start of a Phase III clinical trial and administration of the investigational drug manufactured by the Company. - FY2025AdvancedAnnual report
「In May 2025, as its first project, the Company entered into a basic development agreement for NPC-29, a ubiquinol-containing formulation indicated for multiple system atrophy (MSA). The Company will make every effort to deliver the formulation to patients as soon as possible, while actively pursuing discussions on its second project and advancing development.」
Under the orphan drug business agreement with ノーベルファーマ株式会社, the Company entered into a basic development agreement for its first project, NPC-29, and began discussions on its second project. - FY2024First statedAnnual report
「Accordingly, as one form of entry into new businesses, our Group will develop the field of orphan drug development and contract services. As one example of an alliance with a partner company, our Group entered into an agreement with ノーベルファーマ株式会社 on 18 June 2024 to establish a partnership. ノーベルファーマ株式会社 has a strong track record among leading domestic companies in orphan drug development. Going forward, ノーベルファーマ株式会社 and our Group will combine their complementary strengths to promote the orphan drug business.」
In light of slowing growth in Japan’s generic drug market and declining drug prices, the Company entered the orphan drug development and contract services business with Japan, the United States and Europe in view, and disclosed that it entered into an agreement with ノーベルファーマ株式会社 on 18 June 2024.